GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Margin of Safety % (DCF Dividends Based)

Arcutis Biotherapeutics (Arcutis Biotherapeutics) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Arcutis Biotherapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based) falls into.


Arcutis Biotherapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Margin of Safety % (DCF Dividends Based)
Comparable Companies
NUVB ZURA EPIX HUMA ACIU CELC CMPX FULC XOMA XERS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Website
https://www.arcutis.com
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Executives
Masaru Matsuda officer: SVP and General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett officer: See Remarks C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe director, officer: President and CEO C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney officer: Senior VP, Manufacturing C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne officer: Chief Technical Officer
Kenneth A. Lock officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore officer: SVP and Chief Business Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan director 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656